We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Molecular Assay Detects Clostridium difficile Toxin B Gene

By LabMedica International staff writers
Posted on 01 Dec 2008
Print article
A molecular assay rapidly detects the toxin B gene found in toxigenic Clostridium difficile, the bacterial pathogen responsible for C. difficile infection (CDI). It is the first CDI molecular diagnostic that offers sensitivity, simplicity, and speed in one test procedure.

The test, performed directly from stool specimens, targets the toxin B gene found in toxigenic C. difficile strains, including the BI/NAP1/027 epidemic strain associated with a major CDI outbreak in 2003. It can lead to a definitive diagnosis in less than two hours and may facilitate earlier and more appropriate antibiotic treatment of CDI patients. It may also lead to earlier implementation of infection controls.

Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA) has added this test, which is called the GeneOhm Cdiff assay, to its expanding menu of rapid molecular tests to help prevent healthcare-associated infections, including tests for Staphylococcus aureus and methicillin-resistant S. aureus (MRSA). In addition, BD recently submitted a test to detect the resistant genes associated with vancomycin-resistant Enterococci to Health Canada (Ottawa, ON, Canada) for licensure.

Until now, diagnosing CDI rapidly has proven difficult. Traditional methods, including immunoassays, lack sufficient sensitivity, while tissue culture cytotoxicity methods are difficult to perform and require several days to yield results.

BD announced that Health Canada has licensed the new BD GeneOhm: "Clostridium difficile poses a significant challenge for healthcare facilities across Canada," said Jay Glasscock, Vice President and General Manager, BD in Canada. "We applaud Health Canada for fast-tracking the licensing of this important new test, which will help provide more definitive and more rapid diagnoses of CDI patients. The BD GeneOhm Cdiff assay was developed by BD research scientists in Quebec and will be produced in our new manufacturing facility in Parc Technologique du Quebec Metropolitain."

Related Links:
Becton, Dickinson and Company
Health Canada


Gold Member
Turnkey Packaging Solution
HLX
Unit-Dose Packaging solution
HLX
New
Clostridium Difficile Test
VIDITEST C. Difficile Toxin A+B (Card) Rapid Test
New
Blood Culture Identification Fungal Pathogen Panel
cobas eplex BCID-FP panel

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The Accelerate Arc System has been granted US FDA 510(k) clearance (Photo courtesy of Accelerate Diagnostics)

Automated Positive Blood Culture Sample Preparation Platform Designed to Fight Against Sepsis and AMR

Delayed administration of antibiotics to patients with bloodstream infections significantly increases the risk of morbidity and mortality. For optimal therapeutic outcomes, it is crucial to rapidly identify... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.